Trial Profile
A Study to Evaluate the Efficacy and Tolerability of Eslicarbazepine as Add-on Therapy in Patients With Refractory Partial Epilepsy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Feb 2016
Price :
$35
*
At a glance
- Drugs Eslicarbazepine acetate (Primary)
- Indications Partial epilepsies
- Focus Adverse reactions; Therapeutic Use
- 23 Feb 2016 New trial record